May 10 (Reuters) - Pfizer Canada PFE (NYSE:PFE).N
* Health Canada has provided conditional approval of IBRANCE
TM (palbociclib) and it is now available in canada
Source text for Eikon: ID:nCNWzXzD5a
Further company coverage: PFE.N
(Bengaluru Newsroom: +1 646 223 8780)